Lightnews — Scholar-powered news

Tim Elliott @timmunologist.bsky.social · Jul 20

@blackwellbooks.bsky.social please start posting

Reposted by Tim Elliott

Françoise Howe @francoiseshowe.bsky.social · Jul 19

Great to see our work on preventive cancer vaccines, including LungVax, featured in this issue!

@oxfordcancer.bsky.social @sarahblagden.bsky.social @timmunologist.bsky.social

The Economist @economist.com · Jul 19

Progress in the fight against the disease has been slow, steady—and remarkable. Long may that continue

The world is winning the war on cancer

Progress has been remarkable. Death rates are down substantially, and are likely to fall further

econ.st

2 4

Reposted by Tim Elliott

Oxford Cancer @oxfordcancer.bsky.social · Jul 18

Join us for our DPhil in Cancer Science Open Day on Tuesday 2nd September at 12:30pm to find out how a DPhil can be the next step in your cancer research career development!

Register via our Eventbrite link before 1st Sept⬇️ @oncology.ox.ac.uk @medsci.ox.ac.uk

www.eventbrite.co.uk/e/university...

University of Oxford - DPhil in Cancer Science Open Day

Join the Virtual DPhil in Cancer Science Open Day to hear more about Oxford’s world-leading research training

www.eventbrite.co.uk

2

Tim Elliott @timmunologist.bsky.social · Jul 17

Looking forward to talking about #cancervaccines to *all* @CRUK research and innovation staff this afternoon at their fabulous away-day. Actually I’m a bit nervous😬

1 9

Reposted by Tim Elliott

Hallou Lab @halloulab.bsky.social · Jul 16

Amazing news for our Institute @kiroxford.bsky.social @ox.ac.uk 🎉🍾😀 ! Looking forward to working with our @manchester.ac.uk colleagues to understand better how envrionmental determinants drive chronic inflammatory diseases !

Kennedy Institute of Rheumatology @kiroxford.bsky.social · Jul 16

Huge news! A £50M MRC CoRE will bring together Manchester & Oxford to study how environmental exposures cause chronic inflammatory disease.

The CoRE will be Directed by Prof Judi Allen (Manchester) & co-Directed by Prof Dame Fiona Powrie, Director of the KIR.

www.kennedy.ox.ac.uk/news/new-ps5...

New £50m MRC Centre to study how environmental exposures cause chronic inflammatory diseases

A new Medical Research Council Centre of Research Excellence (MRC CoRE) will investigate how the environment interacts with our immune system to trigger chronic inflammatory diseases, such as asthma, ...

www.kennedy.ox.ac.uk

1 6

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jul 15

Targeting monocyte dynamics in MS?

In Immunotherapy Advances, Bibi et al. explore how shifting monocytes from inflammatory to reparative states may reshape MS treatment strategies.

📘 https://bit.ly/3EXOfaV
##MS #Monocytes #Neuroinflammation

1 1

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jul 14

New research by Rui Zhao et al. shows that high anti-drug antibody (ADA) levels after 3 cycles of camrelizumab are linked to shorter survival in patients with advanced solid cancers.

📉 Higher ADA = lower drug levels = worse outcomes.

🔗 https://bit.ly/461mc5B
##Immunotherapy #CancerResearch

1

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jul 4

🧬 Better understanding of immune rejection and evasion is setting the stage for next-gen therapies.

Elizabeth Simpson reviews how foundational immunology is reshaping transplant and cancer treatment.

📖 https://bit.ly/44N141N
##TransplantImmunology #Immunotherapy

1 1

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jul 6

🧩 Antigen presentation is complex - but imaging is bringing clarity.

@doreenlau.bsky.social‬ & @timmunologist.bsky.social‬ review how advanced imaging illuminates T-cell–APC interactions, peptide-MHC dynamics, and more in cancer immunity.

📖 https://bit.ly/3TkIasN
##CancerImmunology

4 17

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jul 10

A high-affinity TCRxCD3 bispecific (ImmTAC®) efficiently redirects T cells to kill PRAME+ tumor cells, even at low epitope density. Combination with anti-PD-1 restores activity in exhausted T cells.

One of the most read articles in ITA: https://bit.ly/40o5kT8
##immunology

1

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jul 11

Mechanistic modelling reveals that both antigen-dependent and independent factors shape CAR T-cell dynamics in month-one lymphoma patients. IL-7/IL-15 levels and lymphodepletion matter more than CAR T-cell phenotype.

📖 Read: https://bit.ly/3U6fDY6
##Immunotherapy

3 4

Reposted by Tim Elliott

Centre for Immuno-Oncology @oxcio.bsky.social · Jul 10

Yesterday we finished with prize-giving and drinks in the garden🥂🌱! 🏆 Posters for Bas, Cindy & Charlotte📃; postdoc talk for Qian 👩‍🏫 & best embossing artwork for Group8 🧑‍🎨 Shoutout to Lisha for the Rhodes House tours, acknowledging its history, the good and the uncomfortable ⚖️. What a day! #CIOawayday

3 4

Reposted by Tim Elliott

Centre for Immuno-Oncology @oxcio.bsky.social · Jul 9

✨ Kicking off #CIOawayday with our senior PIs sharing the experiments that changed their careers 🧑‍🔬👩‍🔬🧫 A reminder that serendipity, curiosity, and pub chats can spark groundbreaking ideas 🤓 Clearly science thrives on kindness and collaboration and we got a lot of that in #CIO 😉🙃 #ScienceLife

5 7

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jul 12

🔬 Call for papers: We invite submissions for a special collection on Immunotherapies for Inborn Errors of Immunity.

Explore genetics-guided, targeted treatments for primary immunodeficiency and immune dysregulation.

🗓️ Submit by Sept 2025

📖 Info: https://bit.ly/40o5kT8
##Immunotherapy

1

Reposted by Tim Elliott

Patrick McGuire @pjmcg.bsky.social · Jul 12

#Bridge2ABetterFuture Challenge #10 complete with sueduncombe.bsky.social - the @cancerresearch.uk.org Big Hike (Cotswolds). 14 miles over the hills in the heatwave! Big steps bringing big discoveries Thanks for all donations fundraise.cancerresearchuk.org/page/bridge-... @oxfordcancer.bsky.social

2 3

Tim Elliott @timmunologist.bsky.social · Jul 5

Wonderful personal perspective from one of the founders of modern immunology

Immunotherapy Advances @imtadvances.bsky.social · Jul 4

🧬 Better understanding of immune rejection and evasion is setting the stage for next-gen therapies.

Elizabeth Simpson reviews how foundational immunology is reshaping transplant and cancer treatment.

📖 https://bit.ly/44N141N
##TransplantImmunology #Immunotherapy

3

Reposted by Tim Elliott

Centre for Personalised Medicine @cpmoxford.bsky.social · Jul 4

www.um.edu.mo/news-and-pre...

Oxford professor gives talk on application of genomics in modern medicine at UM | University of Macau

The University of Macau: An International Public Comprehensive University Founded in 1981

www.um.edu.mo

1 1 1

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jun 27

🚨 Last chance!

Just a few days left to submit to our Special Collection: Imaging in Immunotherapy.

Showcase your research in molecular imaging, immune monitoring, and image-guided drug delivery.

Deadline: June 2025 🧬🖼️ #Immunotherapy #MolecularImaging

📩 Submit now: https://bit.ly/4j8c265

1 1

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jun 25

🚨 Researchers at over 120 UK institutions can publish open access for free in Immunotherapy Advances!

No APC's, just impactful immunotherapy research shared with the world. 🌐 #OpenScience

🔗 Check eligibility here: bit.ly/4no9OTy

1 2

Reposted by Tim Elliott

Immunotherapy Advances @imtadvances.bsky.social · Jun 26

🫁 New study: M2 macrophages ease asthma symptoms in mice by boosting IL-10⁺ B-cell production via the TGF-β & oxidative phosphorylation pathways.

💡 Highlights the regulatory role of macrophage–B cell interactions in asthma.

🔗 Read more: https://bit.ly/4kXzogj

1 2

Reposted by Tim Elliott

Centre for Immuno-Oncology @oxcio.bsky.social · Jun 26

A big part of the CIO team will be at #BSI2025 🤓 especially now that our very own Max from the @ggillesp.bsky.social lab is featured on the conference poster! Looking forward to an exciting few days in Liverpool 🔬✨ #Immunology #CIOonTour

British Society for Immunology @britsocimm.bsky.social · Jun 25

🚨 Abstract submissions are OPEN for the British Society for Immunology Congress 2025! #BSI25

Join 1,500+ immunologists in Liverpool between 1–4 Dec, for 4 days of science, workshops & networking.

Submit your abstract by 3 Sept & showcase your research! 🔗 bit.ly/4kYXvLN

2 6

Reposted by Tim Elliott

Oxford Cancer @oxfordcancer.bsky.social · Jun 26

And we're off!

Conference Co-Chair and @oncology.ox.ac.uk's Professor of Experimental Oncology @sarahblagden.bsky.social opens day two of the Cancer Prevention Research Conference in London.

3 3

Tim Elliott @timmunologist.bsky.social · Jun 26

Intramolecular Active displacement of common MHC I- peptide interactions drives peptide editing. Thanks for the call out Chris!

Chris Thorpe @drchristhorpe.bsky.social · Jun 26

Fascinating preprint from @timmunologist.bsky.social @mjwsim.bsky.social and co-authors

bioRxiv Immunology @biorxiv-immuno.bsky.social · Jun 25

Atom-level mechanism of tapasin-independent peptide editing by Major Histocompatibility Complex class I molecules https://www.biorxiv.org/content/10.1101/2025.06.20.660712v1

2

Tim Elliott @timmunologist.bsky.social · Jun 25

Really important to see the research generating a solid and powerful evidence base needed to help governments undo health inequalities

Anbu Paramasivam @anbup.bsky.social · Jun 25

A powerful session at #PrevConf25 on why health inequalities must be front and centre in cancer risk and primary prevention—co-chaired by Profs Davis & Bhatla, with key insights from Prof Chambwe, Prof Chibwesha, Dr McCullough & @countthedead.bsky.social.

5

Tim Elliott @timmunologist.bsky.social · Jun 25

It’s under publicised that MANY universities and institutions around the world can publish in ITA for FREE under the read and publish deals with OUP. There are still inequalities - especially painful for BRIC who have great research infrastructure but no R&P deals yet. I hope this will change.

Immunotherapy Advances @imtadvances.bsky.social · Jun 25

🚨 Researchers at over 120 UK institutions can publish open access for free in Immunotherapy Advances!

No APC's, just impactful immunotherapy research shared with the world. 🌐 #OpenScience

🔗 Check eligibility here: bit.ly/4no9OTy

2